Print

EJNMAhmadzadehfar, H., Rahbar, K., Baum, R.P. et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging (2020). https://doi.org/10.1007/s00259-020-04797-9

WARMTH demonstrated in a multicenter study the impact of prior therapies, especially chemotherapy, on the overall survival (OS) of patients with castration-resistant prostate cancer (CRPC) who were receiving [177Lu]Lu-PSMA-617 therapy. In this study, 11 clinics combined their patients’ data to provide a large number of patients for statistical analysis with high power.

This retrospective study was approved by the Ethical Committee of the Medical University of Innsbruck.

Data of 416 patients were analyzed. The study’s inclusion criteria required that all the patients had to have been pretreated with abiraterone, enzalutamide, or both or had to exhibit documented, progressive disease under ongoing therapy with one of those agents. About 75% of the patients received at least one line of chemotherapy. The median OS was 11.1 months whereas the patients without prior chemotherapy showed a significantly longer OS of 14.6 months. This remained independent in the multivariate analysis in addition to the presence of bone and liver metastases as negative prognosticators for survival whereas an ECOG of 0–1 is associated with a longer OS.